Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Pharmaessentia Corp (6446 TT): Stellar 2Q Performance; Eye on Imminent Label Expansion of Besremi

Pharmaessentia Corp (6446 TT): Strong 2Q25; Geography Expansion of Besremi to Drive Near-Term Growth

Pharmaessentia Corp (6446 TT): Strong Start of 2025; Growth Momentum to Continue

Pharmaessentia Corp (6446 TT): Ends 2025 on Strong Note; Key Drug Awaiting Label Expansion in 2026

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaessentia-corp" target="_blank" data-smartkarma-citation="entities:16461:1" rel="noopener">Pharmaessentia Corp (6446 TT)</a> has started 2026 on strong note. 1Q26 revenue reached a record high of NT$5.1B, marking the 14th consecutive quarter of record-high performance with 57% YoY growth.</li>
<li>The company has appointed Incyte alumni Eric Vogel as U.S. Head of Commercialization, thereby strengthening commercial infrastructure ahead of the target action date for in ET on August 30, 2026.</li>
<li>By acquiring 100% of Forus, Pharmaessentia will fully integrate Canadian regulatory and medical affairs, marketing, and commercial channel resources — consolidating competitive advantages for Besremi and future products in the market.</li>
</ul>



Pharmaessentia Corp (6446 TT) has started 2026 on strong note. 1Q26 revenue reached a record high of NT$5.1B, marking the 14th consecutive quarter of record-high performance with 57% YoY growth.
The company has appointed Incyte alumni Eric Vogel as U.S. Head of Commercialization, thereby strengthening commercial infrastructure ahead of the target action date for in ET on August 30, 2026.
By acquiring 100% of Forus, Pharmaessentia will fully integrate Canadian regulatory and medical affairs, marketing, and commercial channel resources — consolidating competitive advantages for Besremi and future products in the market.


Pharmaessentia Corp (6446 TT): Strong 1Q Result; Commercialization Activity Ahead of Label Expansion